Search This Blog

Thursday, July 16, 2020

Heron launches mid-stage study of aprepitant for COVID-19

Heron Therapeutics (NASDAQ:HRTX) perks up 3% premarket in response to its announcement that it has initiated its Phase 2 clinical trial, GUARDS-1, evaluating Cinvanti (aprepitant) in early hospitalized adult COVID-19 patients.
The company posted the study in ClinicalTrials.gov on Tuesday.

Thermo Fisher ups bid for Qiagen

Listening to calls to revise its offer for diagnostic kit maker Qiagen (NYSE:QGEN) amid bullish pandemic-stoked demand, Thermo Fisher Scientific (NYSE:TMO) has increased its per-share cash bid 10% to €43 from €39.
The amended deal includes a reduction in the minimum acceptance threshold to 66.67% of QGEN’s share capital from 75.00%.
QGEN’s board unanimously backs the amended agreement.
The acceptance period has been extended to August 10.
QGEN up 3% premarket.

AC Immune up big on advancement of Alzheimer’s vaccine study

Thinly traded small cap AC Immune (NASDAQ:ACIU) jumps 92% premarket in reaction to its announcement that it has initiated the medium dose cohort in its 24-subject Phase 1b/2a clinical trial evaluating Alzheimer’s disease (AD) anti-Tau vaccine candidate ACI-35.030 in patients with early AD.
The company advanced to the next dose level based on encouraging preliminary safety, tolerability and immunogenicity data from the low dose group.
It is developing the vaccine, designed to generate a specific antibody response against pathologic phospho-Tau proteins in the brain, with Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceuticals.
The estimated primary completion date is October 2022.

Amid virus crisis, U.S. bars imports of Malaysia’s Top Glove over labor issues

U.S. Customs placed a detention order on imports of products made by subsidiaries of the world’s largest medical glove maker, Malaysia’s Top Glove Corp Bhd, an action taken against firms suspected of using forced labour.
The bar on Top Glove products comes at a time when demand for medical gloves and protective gear has skyrocketed due to the coronavirus pandemic, which has hit the United States harder than any other country.
The U.S. Customs and Border Protection (CBP) website showed Top Glove Sdn Bhd and TG Medical Sdn Bhd were placed on its list on Wednesday but there was no statement explaining the action, though its “withhold and release” orders, detaining imported goods, are specific to forced labour issues.
Top Glove, which also has production facilities in China and Thailand, said the move might be related to foreign labour issues, specifically recruitment fees paid by migrant workers to employment agents.
“We are reaching out to the CBP through our office in U.S., customers and consultants, to understand the issue better and work towards a speedy resolution of the matter, within an estimated 2 weeks,” it said in a bourse filing.
In a conference call, Top Glove bosses told reporters and analysts that shipments from the two units represent half of its U.S. sales, and 12.5% of its group sales. However, the group said other subsidiaries could still sell to the U.S. and that others countries would easily take up the returned shipments.
“We continue to ship because we can ship. Worst comes to worst, other countries will take up as well because the order book is more than 100%,” Executive Chairman Lim Wee Chai said on the call about already logging orders for up to 18 months ahead.
Top Glove said it had been bearing all recruitment fees since the start of this year, but it had still to resolve an issue regarding retrospective payment of recruitment fees paid, without its knowldege, by workers to agents before January 2019.
SHARE PRICE SLIPS A LITTLE
“Over the past few months we have been working on this issue, which involves extensive tracing, to establish the correct amount to be paid back to our workers, on behalf of the previous agents,” the company said.
A Reuters query reached CBP outside its office hours.
Top Glove’s share price had slipped 2.57%, a minor blip after a rise of over 350% this year.
Last year, CBP took similar action against another Malaysian glove maker, WRP Asia Pacific Sdn Bhd. The detention order on imports of WRP’s goods was lifted in March after remedial action was taken.
Top Glove Managing Director Lee Kim Meow said the company has engaged the same consultant that had advised WRP on the matter. He did not name the consultant.
“We have engaged them today and already set a plan in motion to take us quickly out of this detention order,” he said.
Independent migrant worker rights specialist Andy Hall said in a note to reporters on Thursday that forced foreign labour in Malaysia’s gloves industry can only be addressed and reduced when past recruitment fees and related costs, which hold such workers in debt bondage, are fully repaid.
“In order to ensure no future debt bondage of these workers, ethical recruitment practices or zero cost recruitment policies should be put in place in practice, if the industry moves ahead to recruit more foreign workers in the future,” he said.
World consumption of protective gloves is expected to jump more than 11% to 330 billion pieces this year, two-thirds of which are likely to be supplied by Malaysia, according to the Southeast Asian country’s rubber glove manufacturers group.
Top Glove’s annual glove production is 78.7 billion pieces, and its 45 factories also make face masks, condoms and dental products. During a results briefing last month, the company said it had achieved unparalleled growth, boosted by an increase i demand from almost everywhere.

NOVO NORDISK: Goldman Sachs gives a Buy rating

In a research note published by Keyur Parekh, Goldman Sachs advises its customers to buy the stock. The target price remains set at DKK 475.

Impact of host resistance on cumulative mortality and herd immunity threshold for SARS-CoV-2

Abstract

It is widely believed that the herd immunity threshold (HIT) required to prevent a resurgence of SARS-CoV-2 is in excess of 50% for any epidemiological setting. Here, we demonstrate that HIT may be greatly reduced if a fraction of the population is unable to transmit the virus due to innate resistance or cross-protection from exposure to seasonal coronaviruses. The drop in HIT is proportional to the fraction of the population resistant only when that fraction is effectively segregated from the general population; however, when mixing is random, the drop in HIT is more precipitous. Significant reductions in expected mortality can also be observed in settings where a fraction of the population is resistant to infection. These results help to explain the large degree of regional variation observed in seroprevalence and cumulative deaths and suggest that sufficient herd-immunity may already be in place to substantially mitigate a potential second wave.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Nothing to declare.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes

Johnson & Johnson Raises 2020 Earnings Guidance

Johnson & Johnson on Thursday raised its revenue and earnings guidance for 2020 compared with forecasts it had issued in April.
The global health-products giant now expects adjusted earnings per share of $7.75 to $7.95 for the year, compared with the earlier forecast of $7.50 to $7.90. Analysts polled by FactSet were anticipating adjusted earnings per share of $7.75.
J&J now expects 2020 revenue of $79.9 billion to $81.4 billion, up from the prior guidance range of $77.5 billion to $80.5 billion. Analysts had forecast revenue of $79.77 billion.
The company says the new guidance includes the estimated impact of the coronavirus pandemic.